RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).
2013; Lippincott Williams & Wilkins; Volume: 31; Issue: 15_suppl Linguagem: Inglês
10.1200/jco.2013.31.15_suppl.1
ISSN1527-7755
AutoresMark R. Gilbert, James J. Dignam, Minhee Won, Deborah T. Blumenthal, Michael A. Vogelbaum, Kenneth Aldape, Howard Colman, Arnab Chakravarti, Robert Jeraj, Terri S. Armstrong, Jeffrey S. Wefel, Paul D. Brown, Kurt A. Jaeckle, David Schiff, James N. Atkins, David Brachman, Maria Werner‐Wasik, Ritsuko Komaki, Erik P. Sulman, Minesh P. Mehta,
Tópico(s)Cancer Research and Treatments
Resumo1 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Sunday, June, 2, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
Referência(s)